Financials
Half-year Report | Jul. 25, 2024 |
1st Quarter Results | Apr. 25, 2024 |
9M and Q3 2023 results | Nov. 09, 2023 |
Half-year Report | Jul. 28, 2023 |
1st Quarter Results | Apr. 27, 2023 |
AZ 2022 Annual Report XBRL | Feb. 21, 2023 |
Annual Financial Report | Feb. 21, 2023 |
Proxies
Special Business Approved at AGM | Apr. 12, 2024 |
Proxy Form for 2024 AGM | Mar. 07, 2024 |
Notice of AGM | Mar. 07, 2024 |
Notice of AGM | Mar. 07, 2024 |
Special Business Approved at AGM | Apr. 27, 2023 |
Result of AGM | Apr. 27, 2023 |
Notice of AGM | Mar. 22, 2023 |
Ownership Update
Director/PDMR Shareholding | Jun. 12, 2024 |
Director/PDMR Shareholding | May. 15, 2024 |
Director/PDMR Shareholding | Mar. 12, 2024 |
Director/PDMR Shareholding | Mar. 06, 2024 |
Director/PDMR Shareholding | Mar. 06, 2024 |
Director/PDMR Shareholding | Feb. 22, 2024 |
Director/PDMR Shareholding | Dec. 14, 2023 |
Announcements
Tezspire nasal polyps trial met primary endpoints | Nov. 08, 2024 |
AZN share price movement | Nov. 05, 2024 |
Total Voting Rights | Nov. 01, 2024 |
AZN China President under investigation | Oct. 30, 2024 |
Wainzua recommended for approval in the EU | Oct. 21, 2024 |
AstraZeneca licenses lipid lowering Lp(a) asset | Oct. 07, 2024 |
Total Voting Rights | Oct. 01, 2024 |
Prospectuses
AstraZeneca prices a €1.4bn bond offering | Jul. 30, 2024 |
AstraZeneca prices a $5bn bond offering | Feb. 22, 2024 |
AstraZeneca prices a $2.25bn bond offering | Mar. 01, 2023 |
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | Jun. 15, 2022 |
AstraZeneca prices a EUR800m bond offering | May. 27, 2021 |
AstraZeneca prices a $7bn bond offering | May. 26, 2021 |
AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | May. 24, 2021 |